BioAtla Q3 net loss $15.8M; FDA aligns on Phase 3 Oz-V design; partnership on track by year-end

BioAtla, Inc.

2025-Q3 EPS reported -$0.85

Q3 2025 net loss $15.8M vs $10.6M in 2024 (which included $11M Context collaboration revenue); cash $8.3M at Sept 30.
FDA alignment achieved on Phase 3 Oz-V trial for 2L+ OPSCC; dual primary endpoints (ORR and OS) with potential accelerated approval.
Company in advanced stages to finalize a strategic transaction by year-end; Context milestone payment of $2M received.
BA3182 (CAB-EpCAM x CD3 TCE) Phase 1 dose escalation ongoing; readout expected in first half 2026.
R&D expenses decreased to $9.5M from $16.4M due to program prioritization and workforce reduction in March 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.